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ABSTRACT
The coronavirus 2019 (COVID-19) respiratory disease is caused by the novel coronavirus SARS-CoV-2 (severe acute respiratory syndrome
coronavirus 2), which uses the enzyme ACE2 to enter human cells. This disease is characterized by important damage at a multi-organ level,
partially due to the abundant expression of ACE2 in practically all human tissues. However, not every organ in which ACE2 is abundant
is affected by SARS-CoV-2, which suggests the existence of other multi-organ routes for transmitting the perturbations produced by the
virus. We consider here diffusive processes through the protein–protein interaction (PPI) network of proteins targeted by SARS-CoV-2
as an alternative route. We found a subdiffusive regime that allows the propagation of virus perturbations through the PPI network at a
significant rate. By following the main subdiffusive routes across the PPI network, we identify proteins mainly expressed in the heart, cerebral
cortex, thymus, testis, lymph node, kidney, among others of the organs reported to be affected by COVID-19.
Published under license by AIP Publishing. https://doi.org/10.1063/5.0015626
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
is the new coronavirus causing the pandemic known as coro-
navirus disease 2019 (COVID-19). This respiratory disease is
characterized by multi-organ and systemic damages in patients.
The abundance of ACE2 on human organs has been claimed
as responsible for such multi-organ spread of the virus dam-
ages. However, once on circulation, the virus could spread to
practically every organ in the human body as ACE2 is ubiq-
uitous on endothelia and smooth muscle cells of virtually all
organs. Contrastingly, SARS-CoV-2 only damages selectively a
few organs. Here, we develop the hypothesis that the effects of
the SARS-CoV-2 virus can be spread through the human pro-
tein–protein interaction (PPI) network in a subdiffusive way.
We then elaborate a time-fractional diffusion model on net-
works, which allow us to study this phenomenon. Starting the
diffusion from the SARS-CoV-2 spike protein to the human PPI
network, we show here that the perturbations can spread across
the whole network in a very few steps. Consequently, we dis-
cover a few potential routes of propagation of these perturbations
from proteins mainly expressed in the lungs to proteins mainly
expressed in other different tissues, such as the heart, cerebral
cortex, thymus, lymph node, testis, prostate, liver, small intestine,
duodenum, kidney, among others already reported as damaged by
COVID-19.
I. INTRODUCTION
Since December 2019, a new coronavirus designated SARS-
CoV-2 (severe acute respiratory syndrome coronavirus 2)1 has pro-
duced an outbreak of pulmonary disease, which has soon become a
global pandemic.2,3 The new coronavirus 2019 (COVID-19) disease
is characterized by a wide range of clinical manifestations,4,5 with an
important implication of multi-organ and systemic dysfunctions,6,7
which include heart failure, renal failure, liver damage, shock, and
multi-organ failure. The new coronavirus shares about 82% of its
genome with the one that produced the 2003 outbreak (SARS-
CoV).8 Both coronaviruses share the same cellular receptor, which
is the angiotensin-converting enzyme 2 (ACE2) receptor.8–10 ACE2
receptors are enriched in several tissues across the organs, such
as in alveolar epithelial type II cells of lung tissues, in the heart,
endothelium, kidneys, and intestines. Therefore, ACE2 has been
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hypothesized as a potential cause of the major complications of the
COVID-19.11,12 However, it has been found that ACE2 has abundant
expression on endothelia and smooth muscle cells of virtually all
organs.13 Therefore, it should be expected that after SARS-CoV-2 is
present in circulation, it can be spread across all organs. In contrast,
both SARS-CoV and SARS-CoV-2 are found specifically in some
organs but not in others, as shown by in situ hybridization studies
for SARS-CoV. This was already remarked by Hamming et al.13 by
stressing that it “is remarkable that so few organs become viruspos-
itive, despite the presence of ACE2 on the endothelia of all organs
and SARS-CoV in blood plasma of infected individuals.” Recently,
Gordon et al.14 identified human proteins that interact physically
with those of the SARS-CoV-2 forming a high confidence SARS-
CoV-2-human protein–protein interaction (PPI) system. Using this
information, Gysi et al.15 discovered that 208 of the human proteins
targeted by SARS-CoV-2 forms a connected component inside the
human PPI network. That is, these 208 are not randomly distributed
across the human proteome, but they are closely interconnected by
short routes that allow moving from one to another in just a few
steps. These interdependencies of protein–protein interactions are
known to enable that perturbations on one interaction propagate
across the network and affect other interactions.16–19 In fact, it has
been signified that diseases are a consequence of such perturba-
tion propagation.20–22 It has been stressed that the protein–protein
interaction process requires diffusion in their initial stages.23 The
diffusive processes occur when proteins, possibly guided by electro-
static interactions, need to encounter each other many times before
forming an intermediate.24 Not surprisingly, diffusive processes have
guided several biologically oriented searches in PPI networks.25,26
Therefore, we assume here that perturbations produced by SARS-
CoV-2 proteins on the human PPI network are propagated by means
of diffusive processes. However, due to the crowded nature of the
intra-cell space and the presence in it of spatial barriers, subdiffu-
sive processes more than normal diffusion are expected for these
protein–protein encounters.27–29 This creates another difficulty, as
remarked by Batada et al.,23 which is that such (sub)diffusive pro-
cesses along are not sufficient for carrying out cellular processes at a
significant rate in cells.
Here, we propose the use of a time-fractional diffusion model
on the PPI network of proteins targeted by SARS-CoV-2. The goal
is to model the propagation of the perturbations produced by the
interactions of human proteins with those of SARS-CoV-2 through
the whole PPI. The subdiffusive process emerging from the appli-
cation of this model to the SARS-CoV-2-human PPIs has a very
small rate of convergence to the steady state. However, this pro-
cess produces a dramatic increment of the probability that certain
proteins are perturbed at very short times. This kind of shock wave
effect of the transmission of perturbations occurs at much earlier
times in the subdiffusive regime than at the normal diffusion one.
Therefore, we propose here a switch and restart process in which
a subdiffusive process starts at a given protein of the PPI, perturbs
a few others, which then become the starting point of a new sub-
diffusive process and so on. Using this approach, we then analyze
how the initial interaction of the SARS-CoV-2 spike protein with a
human protein propagates across the whole network. We discover
some potential routes of propagation of these perturbations from
proteins mainly expressed in the lungs to proteins mainly expressed
in other different tissues, such as the heart, cerebral cortex, thy-
mus, lymph node, testis, prostate, liver, small intestine, duodenum,
kidney, among others.
II. MATERIALS AND METHODS
A. Settling a model
The problem we intend to model here is of a large complexity
as it deals with the propagation of perturbations across a network
of interacting proteins, each of which is located in a crowded intra-
cellular space. Therefore, we necessarily have to impose restrictions
and make assumptions to settle our modeling framework. As we
have mentioned in Sec. I, protein encounters should necessarily
occur in subdiffusive ways due to the crowded environment in
which they are embedded, as well as the existence of immobile obsta-
cles such as membranes. By a subdiffusive process, we understand




∼ tκ , (1)
where 0 < κ < 1 is the anomalous diffusion exponent. As observed
by Sposini et al.,30 these anomalous diffusive processes can emerge
from (i) continuous time random walk (CTRW) processes or by
(ii) viscoelastic diffusion processes. In the first case, the “anomaly”
is created by power-law waiting times in between motion events.
This kind of processes is mainly accounted for by the generalized
Langevin equation with the power-law friction kernel as well as by
fractional Brownian motion (FBM). While the first processes are
characterized by the stretched Gaussian displacement probability
density, weak ergodicity, and aging, the second ones are ergodic
processes characterized by the Gaussian density probability distribu-
tion. Therefore, our first task is to discern which of these two kinds
of approaches is appropriate for the current scenario.
We start by mentioning that Weiss et al.31 have analyzed data
from fluorescence correlation spectroscopy (FCS) for studying sub-
diffusive biological processes. They have, for instance, reported
that membrane proteins move subdiffusively in the endoplasmic
reticulum and Golgi apparatus in vivo. Subdiffusion of cytoplas-
matic macromolecules was also reported by Weiss et al.32 using
FCS. Then, Guigas and Weiss27 simulated the way in which the
subdiffusive motion of these particles should occur in a crowded
intracellular fluid. They did so by assigning diffusive steps from a
Weirstrass–Mandelbrot function yielding a FBM. They stated that
CTRW was excluded due to its Markovian nature. In another work,
Szymanski and Weiss33 used FCS and simulations to analyze the sub-
diffusive motion of a protein in a simulated crowded medium. First,
they reported that crowded-induced subdiffusion is consistent with
the predictions from FBM or obstructed (percolation-like) diffusion.
Second, they reported that CTRW does not explain the experimen-
tal results obtained by FCS and should not be appropriated for such
processes.
The time resolution of FCS is in the microsecond range, i.e.,
10−6 s.34 However, an important question on biological subdiffu-
sion may require higher time resolution to be solved. This is the
question of how diffusive processes on short times, while the macro-
molecule has not felt yet the crowding of the environment, is related
to the long-time diffusion. This particular problem was explored
experimentally by Gupta et al.35 by using state-of-the-art neutron
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spin-echo (NSE) and small-angle neutron scattering (SANS), which
has a resolution in the nanosecond range, i.e., 10−9 s. Their experi-
mental setting was defined by the use of two globular proteins in a
crowded environment formed by poly(ethylene oxide) (PEO), which
mimics a macromolecular environment. In their experiments, NSE
was used to tackle the fast diffusion process, which corresponds
to a dynamics inside a trap built by the environment mesh. SANS
captures the slow dynamics, which corresponds to the long-time dif-
fusion at macroscopic length scales. From our current perspective,
the most important result of this work is that the authors found that
in a higher concentration of polymeric solutions, like in the intra-
cellular space, the diffusion is fractional in nature. They showed
this by using the fractional Fokker–Planck equation with a periodic
potential. According to Gupta et al.,35 this fractional nature of the
crossover from fast dynamics to slow macroscopic dynamics is due
to the heterogeneity of the polymer mesh in the bulk sample, which
may well resemble the intra-cellular environment. As proved by
Barkai et al.,36 the fractional Fokker–Planck equation can be derived
from the CTRW, which clearly indicates that the results obtained by
Gupta et al. point out to the classification of the subdiffusive dynam-
ics into the class (i). We should remark that independently of these
results by Gupta et al.,35 Shorten and Sneyd37 have successfully used
the fractional diffusion equation to mimic the protein diffusion in
an obstructed media like within skeletal muscle. We notice in pass-
ing that the (fractional) diffusion equation can be obtained from the
(fractional) Fokker–Planck equation in the absence of an external
force.
In closing, because here we are interested in modeling the dif-
fusion of proteins in several human cells, which are highly crowded,
and in which we should recover the same crossover between ini-
tial fast and later slow dynamics, we will consider a modeling tool
of the class (i). In particular, we will focus our modeling on the
use of a time-fractional diffusion equation using Caputo derivatives.
Another justification for the use of this model here is that interact-
ing proteins can be in different kinds of cells. Thus, we consider
that the perturbation of one protein is not necessarily followed by
the perturbation of one of its interactors, but a time may mediate
between the two processes. This is exactly the kind of processes that
the time-fractional diffusion captures.
B. Time-fractional diffusion model on networks
In this work, we always consider G = (V, E) to be an undirected
finite network with vertices V representing proteins and edges E rep-
resenting the interaction between pairs of proteins. Let us consider
0 < α ≤ 1 and a function u : [0, ∞) → R, then we denote by Dαt u
the fractional Caputo derivative of u of the order α, which is given
by38
Dαt u (t) =
∫ t
0
g1−α (t − τ) u





(t) , t > 0,




, for γ > 0,where 0 (·) is the Euler gamma function.
Observe that the previous fractional derivative has sense whenever
the function is derivable and the convolution is defined (for exam-
ple, if u′ is locally integrable). The notation gγ is very useful in the
fractional calculus theory, mainly by the property gγ ∗ gδ = gγ+δ for
all γ , δ > 0.
Here, we propose to consider the time-fractional diffusion
(TFD) equation on the network as
Dαt x (t) = −CLx (t) , (2)
with the initial condition x (0) = x0, where xi (t) is the probabil-
ity that the protein i is perturbed at the time t; C is the diffusion
coefficient of the network, which we will set hereafter to unity; and
L is the graph Laplacian, i.e., L = K − A, where K is a diagonal
matrix of node degrees and A is the adjacency matrix. This model
was previously studied in distributed coordination algorithms for
the consensus of multi-agent systems.39–41 The use of fractional
calculus in the context of physical anomalous diffusion has been
reviewed by Metzler and Klafter.42 A different approach has been
developed by Riascos and Mateos.43,44 It is based on the use of frac-
tional powers of the graph Laplacian (see Ref. 45 and references
therein). The approach has been recently formalized by Benzi et al.46
This method cannot be used in the current framework because it
generates only superdiffusive behaviors (see Benzi et al.46) and not
subdiffusive regimes. Another disadvantage of this approach is that
it can only be used to positive (semi)definite graph operators, such as
the Laplacian, but not to adjacency operators such as the one used in
tight-binding quantum mechanical or epidemiological approaches
(see Sec. VI).
Theorem 1. The solution of the fractional-time diffusion
model on the network is
x (t) = Eα,1 (− (tC)
α
L) x0, (3)
where Eα,β (γL) is the Mittag–Leffler function of the Laplacian
matrix of a graph.
Proof. We use the spectral decomposition of the network
Laplacian L = UΛU−1, where U =
[
Eψ1 · · · Eψn
]
andΛ = diag (µr).
Then, we can write
Dαt x (t) = −UΛU
−1x (t) . (4)
Let us define y (t) = U−1x (t) such that Dαt x (t) = −UΛy (t),
and we have
U−1Dαt x (t) = −Λy (t) ,
Dαt y (t) = −Λy (t) .
(5)
As3 is a diagonal matrix, we can write
Dαt yi (t) = −µiyi (t) , (6)
which has the solution
yi (t) = Eα,1 (−t
αµi) yi (0) . (7)
We can replace yi (t) = U−1xi (t) to have
U−1xi (t) = Eα,1 (−t
αµi)U
−1xi (0) ,




which finally gives the result in the matrix-vector when written for
all the nodes,
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We can write L = UΛU−1, where U =
[
Eψ1 · · · Eψn
]
and
Λ = diag (µr). Then,
Eα,1 (−t
α
L) = UEα,1 (−t
α3)U−1, (10)
which can be expanded as
Eα,1 (−t
α











where Eψj and Eφj are the jth column of U and of U−1, respectively.






L) = Eψ1 Eφ
T
1 , (12)
where EψT1 Eφ1 = 1. Let us take Eψ1 = E1, such that we have
lim
t→∞
















This result indicates that in an undirected and connected network,
the diffusive process controlled by the TFD equation always reaches
a steady state, which consists of the average of the values of the initial
condition. In the case of directed networks (PPI are not directed by
nature) or in disconnected networks (a situation that can be found
in PPIs), the steady state is reached in each (strongly) connected
component of the graph. Also, because the network is connected,
µ2 makes the largest contribution to Eα,1 (−tαL) among all the
nontrivial eigenvalues of L. Therefore, it dictates the rate of con-
vergence of the diffusion process. We remark that in practice, the
steady state limt→∞ ‖xv (t)− xw (t)‖ = 0, ∀v, w ∈ V is very difficult
to achieve. Therefore, we use a threshold ε, e.g., ε = 10−3, such
that limt→∞ ‖xv (t)− xw (t)‖ = ε is achieved in a relatively small
simulation time.
Due to its importance in this work, we remark the structural
meaning of the Mittag–Leffler function of the Laplacian matrix
appearing in the solution of the TFD equation. That is, Eα,1 (−tαL)











) ,α > 0, (14)
where 0 (·) is the Euler gamma function as before. We remark
that for α = 1, we recover the diffusion equation on the network:
dx (t) /dt = −Lx (t) and its solution E1,1 (−tαL) = exp (−tCL) is
the well-known heat kernel of the graph.
C. Time-fractional diffusion distance
We define here a generalization of the diffusion distance stud-
ied by Coifman and Lafon.47 Let f (τL) = Eα,1 (−tαL), such that
f(τL)vw represents the v, w entry of the matrix function Eα,1 (−t
αL).
Then, we define the following quantity:
Dvw = f (τL)vv + f (τL)ww − 2f (τL)vw . (15)
We have the following result.
Theorem 2. The function Dvw = f(τL)vv + f(τL)ww
− 2f(τL)vw is a Euclidean distance between the corresponding pair
of nodes in the network.
Proof. The matrix function f (τL) can be written as f (τL)
= Uf (τΛ)U−1. Let Eϕu =
[
ψ1,u,ψ2,u, . . . ,ψn,u
]T
. Then,
Dvw = ( Eϕv − Eϕw)
T f (τΛ) ( Eϕv − Eϕw) . (16)
Therefore, because f (τL) is positively defined, we can write
Dvw =
(








f1/2 (τΛ) Eϕv − f
1/2 (τΛ) Eϕw
)T (





Exv (τ )− Exw (τ )
)T (









where Exv (τ ) = f1/2 (τΛ) Eϕv. Consequently, Dvw is a square Euclidean
distance between v and w. In this sense, the vector Exv (τ ) =
f1/2 (τΛ) Eϕv is the position vector of the node v in the diffusion
Euclidean space. 
Because E1,1 (−tαL) = exp (−tαL), we have that Dvw general-
izes the diffusion distance studied by Coifman and Lafon, which is
the particular case when α = 1. Let µj be the jth eigenvalue and ψju
the uth entry of the jth eigenvector of the Laplacian matrix. Then,













It is evident that when α = 1, Dvw is exactly the diffusion
distance previously studied by Coifman and Lafon.47 The fractional-
time diffusion distance between every pair of nodes in a network can
be represented in a matrix form as follows:
Σ (τ) =
(





f(τL)11, f(τL)22, . . . , f(τL)nn
]
is a vector whose entries
are the main diagonal terms of the Mittag–Leffler matrix function, E1
is an all-ones vector, and ◦ indicates an entrywise operation. Using
this matrix, we can build the diffusion distance-weighted adjacency
matrix of the network,
W (τ ) = A ◦Σ (τ) = Σ (τ) ◦ A. (20)
The shortest diffusion path between two nodes is then the
shortest weighted path in W (τ ).
Lemma 3. The shortest (topological) path distance between
two nodes in a graph is a particular case of the time-fractional shortest
diffusion path length for τ → 0.
Proof. Let us consider each of the terms forming the definition
of the time-fractional diffusion distance and apply the limit of the
very small −tα . That is,
lim
τ→0





ψ2rvf (τΛ) = 1, (21)
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and in a similar way,
lim
τ→0










ψrvψrw = 0. (22)
Therefore, lim
τ→0
Dvw (τ ) = 2. Consequently, lim
τ→0
W (τ ) = 2A, which
immediately implies that the time-fractional shortest diffusion path
is identical to the shortest (topological) one in the limit of very small
τ = −tα . 
D. Network of proteins targeted by SARS-CoV-2
The proteins of SARS-CoV-2 and their interactions with
human proteins were determined experimentally by Gordon et al.14
Gysi et al.15 constructed an interaction network of all 239 human
proteins targeted by SARS-CoV-2. In this network, the nodes rep-
resent human proteins targeted by SARS-CoV-2 and two nodes
are connected if the corresponding proteins have been determined
to interact with each other. Obviously, this network of proteins
targeted by SARS-CoV-2 is a subgraph of the protein–protein inter-
action (PPI) network of humans. One of the surprising findings of
Gysi et al.15 is the fact that this subgraph is not formed by proteins
randomly distributed across the human PPI, but they form a main
cluster of 208 proteins and a few small isolated components. Here-
after, we will always consider this connected component of human
proteins targeted by SARS-CoV-2. This network is formed by 193
proteins, which are significantly expressed in the lungs. Gysi et al.15
reported a protein as being significantly expressed in the lungs if its
GTEx median value is larger than 5. GTEx48 is a database contain-
ing the median gene expression from RNA-seq in different tissues.
The other 15 proteins are mainly expressed in other tissues. How-
ever, in reporting here, the tissues that were proteins are mainly
expressed; we use the information reported in The Human Pro-
tein Atlas49 where we use information not only from GTEx but also
from HPA (see details at the Human Protein Atlas webpage) and
FANTOM550 datasets.
III. RESULTS
A. Global characteristics of the time-fractional
diffusion
The PPI network of human proteins targeted by SARS-CoV-2
is very sparse, having 360 edges, i.e., its edge density is 0.0167, 30%
of nodes have a degree (number of connections per protein) equal to
one, and the maximum degree of a protein is 14. The second small-
est eigenvalue of the Laplacian matrix of this network is very small;
i.e., µ2 = 0.0647. Therefore, the rate of convergence to the steady
state of the diffusion processes taking place on this PPI is very slow.
We start by analyzing the effects of the fractional coefficient α on
these diffusive dynamics. We use the normal diffusion α = 1 as the
reference system.
To analyze the effects of changing α over the diffusive dynamics
on the PPI network, we consider the solution of the TFD equation
for processes starting at a protein with a large degree, i.e., PRKACA,
degree 14, and a protein with a low degree, i.e., MRPS5, degree 3.
That is, the initial condition vector consists of a vector having one
at the entry corresponding to either PRKACA or MRPS5 and zeroes
elsewhere. In Fig. 1, we display the changes of the probability with
the shortest path distance from the protein where the process starts.
This distance corresponds to the number of steps that the pertur-
bation needs to traverse to visit other proteins. For α = 1.0, the
shapes of the curves in Fig. 1 are the characteristic ones for the Gaus-
sian decay of the probability with distance. However, for α < 1, we
observe that such decay differs from that typical shape showing a
faster initial decay followed by a slower one. In order to observe this
effect in a better way, we zoomed the region of distances from 2 to
4 [see Figs. 1(b) and 1(d)]. As can be seen for distances below 3, the
curve for α = 1.0 is on top of those for α < 1, indicating a slower
decay of the probability. After this distance, there is an inversion,
and the normal diffusion occurs at a much faster rate than the other
two for the longer distances. This is a characteristic signature of sub-
diffusive processes, which starts at much faster rates than a normal
diffusive process and then continue at much slower rates. Therefore,
here, we observe that the subdiffusive dynamics are much faster at
earlier times of the process, which is when the perturbation occurs
to close nearest neighbors to the initial point of perturbation.
To further investigate these characteristic effects of the sub-
diffusive dynamics, we study the time evolution of a perturbation
occurring at a given protein and its propagation across the whole
PPI network. In Fig. 2, we illustrate these results for α = 1.0 (a),
α = 0.75 (b), and α = 0.5 (c). As can be seen in the main plots of this
figure, the rate of convergence of the processes to the steady state
is much faster in the normal diffusion (a) than in the subdiffusive
one (b) and (c). However, at very earlier times (see insets in Fig. 2),
there is a shock wave increase of the perturbation at a set of nodes.
Such kind of shock waves has been previously analyzed in other con-
texts as a way of propagating effects across PPI networks.17 We have
explored briefly about the possible causes of this increase in the con-
centration for a given subset of proteins. Accordingly, it seems that
the main reason for this is the connectivity provided by the net-
work of interactions and not a given distribution of the degrees.
For instance, we have observed such “shock waves” in networks with
normal-like distributions as well as with power-law ones. However,
it is possible that the extension and intensity of such effects depend
on the degree distribution as well as on other topological factors.
The remarkable finding here is, however, the fact that such a shock
wave occurs at much earlier times in the subdiffusive regimes than
at the normal diffusion. That is, while for α = 1.0, these pertur-
bations occur at t≈0.1–0.3; for α = 0.75, they occur at t≈0.0–0.2;
and for α = 0.5, they occur at t≈0.0–0.1. Seeing this phenomenon
in the light of what we have observed in the previous paragraph is
not strange due to the observation that such processes go at a much
faster rate at earlier times, and at short distances, than the normal
diffusion. In fact, this is a consequence of the existence of a posi-
tive scalar T for which Eα,1 (−γ tα) decreases faster than exp (−γ t)
for t ∈ (0, T) for γ ∈ R+ and α ∈ R+ (see Theorem 4.1 in Ref. 39).
Hereafter, we will consider the value of α = 0.75 for our experi-
ments due to the fact that it reveals a subdiffusive regime, but the
shock waves observed before are not occurring in an almost instan-
taneous way like when α = 0.5 , which would be difficult from a
biological perspective.
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FIG. 1. Spatial propagation of perturbations. The
average probability that a protein at a given dis-
tance from the perturbed protein feels the pertur-
bation. (a) The initiators are the protein PRKACA
(a) and (b) as well as MRPS5 (c) and (d). (b) and
(d) zoom the scale of the processes in (a) and (c),
respectively. The y axis is in a logarithmic scale.
The distance (x axis) refers to the shortest path
distance from the initiator, and the plots are made
“artificially” symmetric for better visualization.
FIG. 2. Shock wave increase of perturbations across the network. Time evolution of the propagation of perturbations from the protein PRKACA to the rest of the proteins in
the PPI network of human proteins targeted by SARS-CoV-2. (a) Normal diffusion α = 1.0. (b) Subdiffusion obtained for α = 3/4. (c) Subdiffusion obtained for α = 1/2.
The insets illustrate the shortest time evolution of the perturbations. Every curve corresponds to a protein in the PPI.
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The previous results put us at a crossroads. First, the subd-
iffusive processes that are expected due to the crowded nature of
the intra-cellular space are very slow for carrying out cellular pro-
cesses at a significant rate in cells. However, the perturbation shocks
occurring at earlier times of these processes are significantly faster
than in normal diffusion. To sort out these difficulties, we propose
a switching back and restart subdiffusive process occurring in the
PPI network. That is, a subdiffusive process starts at a given protein,
which is directly perturbed by a protein of SARS-CoV-2. It produces
a shock wave increase of the perturbation in close neighbors of that
proteins. Then, a second subdiffusive process starts at these newly
perturbed proteins, which will perturb their nearest neighbors. The
process is repeated until the whole PPI network is perturbed. This
kind of “switch and restart processes” has been proposed for engi-
neering consensus protocols in multiagent systems51 as a way to
accelerate the algorithms using subdiffusive regimes.
B. Time-fractional diffusion from the SARS-CoV-2
spike protein
The so-called Spike protein (S-protein) of the SARS-CoV-2
interacts with only two proteins in the human hosts, namely,
ZDHHC5 and GOLGA7. The first protein, ZDHHC5, is not in the
main connected component of the PPI network of SARS-CoV-2
targets. Therefore, we will consider here how a perturbation pro-
duced by the interaction of the virus S-protein with GOLGA7 is
propagated through the whole PPI network of SARS-CoV-2 targets.
GOLGA7 has degree one in this network, and its diffusion is mainly
to close neighbors, namely, to proteins separated by two to three
edges. When starting the diffusion process at the protein GOLGA7,
the main increase in the probability of perturbing another protein
is reached for the protein GOLGA3, which increases its probability
up to 0.15 at t = 0.2, followed by PRKAR2A, with a small increase
in its probability, 0.0081. Then, the process switch and restarts
at GOLGA3, which mainly triggers the probability of the protein
PRKAR2A—a major hub of the network. Once we start the process
at PRKAR2A, practically, the whole network is perturbed with prob-
abilities larger than 0.1 for 19 proteins apart from GOLGA3. These
proteins are in decreasing order of their probability of being per-
turbed: AKAP8, PRKAR2B, CEP350, MIB1, CDK5RAP2, CEP135,
AKAP9, CEP250, PCNT, CEP43, PDE4DIP, PRKACA, TUB6CP3,
TUB6CP2, CEP68, CLIP4, CNTRL, PLEKHA5, and NINL. Notice
that the number of proteins perturbed is significantly larger than the
degree of the activator, indicating that not only nearest neighbors are
activated.
An important criterion for revealing the important role of the
protein PRKAR2A as a main propagator in the network of pro-
teins targeted by SARS-CoV-2 is its average diffusion path length.
This is the average number of steps that a diffusive process start-
ing at this protein needs to perturb all the proteins in the network.
We have calculated this number to be 3.6250, which is only slightly
larger than the average (topological) path length, which is 3.5673.
That is, in less than four steps, the whole network of proteins is acti-
vated by a diffusive process starting at PRKAR2A. Also remarkable
that the average shortest diffusive path length is almost identical to
the shortest (topological) one. This means that this protein mainly
uses shortest (topological) paths in perturbing other proteins in the
FIG. 3. Main disease activators. Proteins targeted by SARS-CoV-2 identified as
the top 20 main activators of proteins that are involved in human diseases.
PPI. In other words, it is highly efficient in conducting such per-
turbations. We will analyze this characteristics of the PPI of human
proteins targeted by SARS-CoV-2 in a further section of this work.
At this time, almost any protein in the PPI network is already
perturbed. Therefore, we can switch and restart the subdiffusion
from practically any protein at the PPI network. We then investi-
gate which are the proteins with the higher capacity of activating
other proteins that are involved in human diseases. Here, we use the
database DisGeNet,52 which is one of the largest publicly available
collections of genes and variants associated with human diseases.
We identified 38 proteins targeted by SARS-CoV-2 for which there
is a “definitive” or “strong” evidence of being involved in a human
disease or syndrome (see Table S1 in the supplementary material).
These proteins participate in 70 different human diseases or syn-
dromes as given in Tables S2 and S3 of the supplementary material.
We performed an analysis in which a diffusive process starts at any
protein of the network, and we calculated the average probability
that all the proteins involved in human diseases are then perturbed.
For instance, for a subdiffusive process starting at the protein ARF6,
we summed up the probabilities that the 38 proteins involved in dis-
eases are perturbed at an early time of the process t = 0.2. Then,
we obtain a global perturbation probability of 0.874. By repeating
this process for every protein as an initiator, we obtained the top
disease activators. We have found that none of the 20 top activa-
tors is involved itself in any of the human diseases or syndromes
considered here. They are, however, proteins that are important not
because of their direct involvement in diseases or syndromes but
because they propagate perturbations in a very effective way to those
directly involved in such diseases/syndromes. Among the top acti-
vators, we have found ARF6, ECSIT, RETREG3, STOM, HDAC2,
EXOSC5, THTPA, among others shown in Fig. 3, where we illustrate
the PPI network of the proteins targeted by SARS-CoV-2 remarking
the top 20 disease activators.
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FIG. 4. Shock wave increase of perturbations
in proteins outside the lungs. Time evolution of
the propagation of perturbations from the protein
GOLGA2 to proteins mainly expressed outside the
lungs. (a) Normal diffusion α = 1.0. (b) Subdiffu-
sion with α = 3/4. The insets illustrate the short-
est time evolution of the perturbation. Every curve
corresponds to a protein in the PPI outside the
lungs.
C. Time-fractional diffusion from the lungs to other
organs
We now consider how a perturbation produced by SARS-
CoV-2 on a protein mainly expressed in the lungs can be prop-
agated to proteins mainly located in other tissues (see Table S4
in the supplementary material) by a subdiffusive process. That
is, we start the subdiffusive process by perturbing a given pro-
tein, which is mainly expressed in the lungs. Then, we observe
the evolution of the perturbation at every one of the proteins
mainly expressed in other tissues. We repeat this process for all
the 193 proteins mainly expressed in the lungs. In every case,
we record those proteins outside the lungs, which are perturbed
at very early times of the subdiffusive process. For instance,
in Fig. 4, we illustrate one example in which the initiator is
the protein GOLGA2, which triggers a shock wave on pro-
teins RBM41, TL5, and PKP2, which are expressed mainly out-
side the lungs. We consider such perturbations only if they
occur at t < 1.
Not every one of the proteins expressed outside the lungs is
triggered by such shock waves at a very early time of the diffusion.
For instance, proteins MARK1 and SLC27A2 are perturbed in very
slow processes and do not produce the characteristic high peaks in
the probability at very short times. On the other hand, there are pro-
teins expressed outside the lungs that are triggered by more than
one protein from the lungs. The case of GOLGA2 is an example
of a protein triggered by three proteins in the lungs. In Table I,
we list some of the proteins expressed mainly in tissues outside the
lungs, which are heavily perturbed by proteins in the lungs. The
TABLE I. Multi-organ propagation of perturbations. Proteins mainly expressed outside the lungs are significantly perturbed during diffusive processes that have started at other
proteins expressed in the lungs. Act. is the number of lung proteins activators, ptot is the sum of the probabilities of finding the diffusive particle at this protein, and tmean is the
average time of activation (see the text for explanations). The tissues of main expression are selected among the ones with the highest Consensus Normalized eXpression (NX)
levels by combining the data from the three transcriptomics datasets (HPA, GTEx, and FANTOM5) using the internal normalization pipeline.49 Boldface denotes the highest value
in each of the columns.
Protein Act. ptot tmean Tissues of the main expression
PKP2 21 0.498 0.29 Heart muscle
CEP43 18 0.521 0.26 Testis
CEP135 14 0.527 0.30 Skeletal muscle, heart muscle, cerebral cortex, cerebellum
TLE5 13 0.509 0.24 Thymus, lymph node, testis
RETREG3 6 0.390 0.43 Prostate, thymus
RBM41 6 0.209 0.49 Pancreas, T-cells, testis, retina
PRIM2 5 0.536 0.30 Cerebellum, parathyroid gland, testis
MIPOL1 3 0.155 0.57 Pituitary gland, testis
REEP6 1 0.175 0.48 Liver, small intestine, duodenum, testis
HOOK1 1 0.156 0.46 Liver, parathyroid gland, testis, pituitary gland
CENPF 1 0.138 0.46 Thymus, testis, bone marrow
ATP5ME 1 0.096 0.35 Skeletal muscle, dendritic cells, heart muscle, brain
TRIM59 1 0.170 0.69 Corpus callosum, brain, T-cells, testis
MARK1 1 N/A >100 Epididymis, cerebral cortex, heart muscle, testis, cerebellum
SLC27A2 1 N/A >100 Liver, kidney
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complete list of the perturbing proteins is given in Table S5 of the
supplementary material. We give three indicators of the importance
of the perturbation of these proteins. They are Act., which is the
number of proteins in the lungs that activate each of them; ptot,
which is the sum of the probabilities of finding the diffusive parti-
cle at this protein for diffusive processes that have started in their
activators; and tmean, which is the average time required by activa-
tors to perturb the corresponding protein. For instance, PKP2 is
perturbed by 21 proteins in the lungs, which indicates that this pro-
tein, mainly expressed in the heart muscle, has a large chance of
being perturbed by diffusive processes starting in proteins mainly
located at the lungs. Protein PRIM2 is activated by 5 proteins in
the lungs, but if all these proteins were acting at the same time, the
probability that PRIM2 is perturbed will be very high, ptot ≈ 0.536.
Finally, protein TLE5 is perturbed by 13 proteins in the lungs, which
needs as an average tmean ≈ 0.24 to perturb TLE5. These proteins
do not form a connected component among them in the network.
The average shortest diffusion path between them is 5.286 with a
maximum shortest subdiffusion path of 10. As an average, they are
almost equidistant from the rest of the proteins in the network as
among themselves. That is, the average shortest subdiffusion path
between these proteins expressed outside the lungs and the rest of
the proteins in the network is 5.106. Therefore, these proteins can
be reached from other proteins outside the lungs in no more than
six steps in subdiffusive processes like the ones considered here.
D. Subdiffusion paths
Finally, we study here how the diffusive process determines the
paths that the perturbation follows when diffusing from a protein to
another not directly connected to it. The most efficient way of prop-
agating a perturbation between the nodes of a network is through
the shortest (topological) paths that connect them. The problem
for a (sub)diffusive perturbation propagating between the nodes
of a network is that it does not have complete information about
the topology of the network as to know its shortest (topological)
paths. The network formed by the proteins targeted by SARS-
CoV-2 is very sparse, and this indeed facilitates that the
perturbations occurs by following the shortest (topological) paths
most of the time. Think, for instance, in a tree, which has the low-
est possible edge density among all connected networks. In this
case, the perturbation will always use the shortest (topological) paths
connecting pairs of nodes. However, in the case of the PPI net-
work studied here, a normal diffusive process, i.e., α = 1, not always
uses the shortest (topological) paths. In this case, there are 1294
pairs of proteins for which the diffusive particle uses a shortest
diffusive path, which is one edge longer than the corresponding
shortest (topological) path. This represents 6.11% of all total pairs
of proteins that are interconnected by a path in the PPI network of
proteins targeted by SARS-CoV-2. However, when we have a subd-
iffusive process, i.e., α = 0.75, this number is reduced to 437, which
represents only 2.06% of all pairs of proteins. Therefore, the subd-
iffusion process studied here through the PPI network of proteins
targeted by SARS-CoV-2 has an efficiency of 97.9% relative to a
process that always uses the shortest (topological) paths in hopping
between proteins. In Fig. 5, we illustrate the frequency with which
proteins not in the shortest (topological) paths are perturbed as a
consequence that they are in the shortest subdiffusive paths between
other proteins. For instance, the following is a shortest diffusive path
between the two end points: RHOA-PRKACA-PRKAR2A-CEP43-
RAB7A-ATP6AP1. The corresponding shortest (topological) path
is RHOA-MARK2-AP2M1-RAB7A-ATP6AP1, which is one edge
smaller. The proteins PRKACA, PRKAR2A, and CEP43 are those
in the diffusive path that are not in the topological one. Repeating
this selection process for all the diffusive paths that differs from the
topological ones, we obtained the results illustrated in Fig. 5. As can
be seen, there are 36 proteins visited by the shortest diffusive paths,
which are not visited by the corresponding topological ones. The
FIG. 5. Proteins in shortest subdiffusive paths.
The frequency of proteins that appears in the
shortest subdiffusion paths but not in the shortest
(topological) paths connecting any pair of nodes in
the PPI network. Bars marked in wine color are for
those proteins expressedmainly outside the lungs.
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average degree of these proteins is 7.28, and there is only a small
positive trend between the degree of the proteins and the frequency
with which they appear in these paths; e.g., the Pearson correlation
coefficient is 0.46.
IV. DISCUSSION
We have presented a methodology that allows the study of dif-
fusive processes in (PPI) networks varying from normal to subdiffu-
sive regimes. Here, we have studied the particular case in which the
time-fractional diffusion equation produces a subdiffusive regime,
with the use of α = 3/4 in the network of human proteins targeted
by SARS-CoV-2. A characteristic feature of this PPI network is that
the second smallest eigenvalue is very small; i.e., µ2 = 0.0647. As
this eigenvalue determines the rate of convergence to the steady
state, the subdiffusive process converges very slowly to that state.
What it has been surprising is that even in these conditions of very
small convergence to the steady state, there is a very early increase
of the probability in those proteins closely connected to the initia-
tor of the diffusive process. That is, in a subdiffusive process on a
network, the time at which a perturbation is transmitted from the
initiator to any of its nearest neighbors occurs at an earlier time
than for the normal diffusion. This is a consequence of the fact that
Eα,1 (−γ t
α) decreases very fast at small values of tα , which implies
that the perturbation occurring at a protein i at t = 0 is transmitted
almost instantaneously to the proteins closely connected to i. This
effect may be responsible for the explanation about why subdiffusive
processes, which are so globally slow, can carry out cellular processes
at a significant rate in cells. We have considered here a mechanism
consisting in switching and restarting several times during the global
cellular process. For instance, a subdiffusive process starting at the
protein i perturbs its nearest neighbors at very early times, among
which we can find the protein j. Then, a new subdiffusive process
can be restarted again at the node j and so on.
One of the important findings of using the current model for
the study of the PIN of proteins affected by SARS-CoV-2 is the iden-
tification of those proteins that are expressed outside the lungs that
can be more efficiently perturbed by those expressed in the lungs
(see Table I). For instance, the protein with the largest number of
activators, PKP2, appears mainly in the heart muscle. It has been
observed that the elevation of cardiac biomarkers is a prominent
feature of COVID-19, which in general is associated with a worse
prognosis.53 Myocardial damage and heart failure are responsible
for 40% of death in the Wuhan cohort (see references in Ref. 53).
Although the exact mechanism involving the heart injury is not
known, the hypothesis of direct myocardial infection by SARS-
CoV-2 is a possibility, which acts along or in combination with the
increased cardiac stress due to respiratory failure and hypoxemia,
and/or with the indirect injury from the systemic inflammatory
response.53–56 As can be seen in Table I, the testis is the tissue
where several of the proteins targeted by SARS-CoV-2 are mainly
expressed, e.g., CEP43, TLE5, PRIM2, MIPOL1, REEP6, HOOK1,
CENPF, TRIM59, and MARK1. Currently, there is no conclusive
evidence about the testis damage by SARS-CoV-2.57–60 However, the
previous SARS-CoV that appeared in 2003 and which shares 82%
of proteins with the current one produced testis damage and sper-
matogenesis, and it was concluded that orchitis was a complication
of that previous SARS disease.57 We also detect a few proteins
mainly expressed in different brain tissues, such as CEP135, PRIM2,
TRIM59, and MARK1. The implication of SARS-CoV-2 and
cerebrovascular diseases has been reported, including neurological
manifestations as well as cerebrovascular disease, such as ischemic
stroke, cerebral venous thrombosis, and cerebral hemorrhage.61–63
Kidney damage in SARS-CoV-2 patients has been reported,64–66
which includes signs of kidney dysfunctions, proteinuria, hematuria,
increased levels of blood urea nitrogen, and increased levels of serum
creatinine. As much as 25% of an acute kidney injury has been
reported in the clinical setting of SARS-CoV-2 patients. One of the
potential mechanisms for kidney damage is the organ crosstalk,64
as can be the mechanism of diffusion from proteins in the lungs
to proteins in the urinary tract and kidney proposed here. A very
interesting observation from Table I is the existence of several pro-
teins expressed mainly in the thymus and T-cells, such as TLE5,
RETREG3, RBM41, CENPF, and TRIM59. It has been reported that
many of the patients affected by SARS-CoV-2 in Wuhan displayed
a significant decrease of T-cells.67 Thymus is an organ that dis-
plays a progressive decline with age with reduction of the order of
3%–5% a year until approximately 30–40 years of age and of about
1% per year after that age. Consequently, it was proposed that the
role of thymus should be taken into account in order to explain why
COVID-19 appears to be so mild in children.67 The protein TLE5 is
also expressed significantly in the lymph nodes. It was found by Feng
et al.68 that SARS-CoV-2 induces lymph follicle depletion, splenic
nodule atrophy, histiocyte hyperplasia, and lymphocyte reductions.
The proteins HOOK1 and MIPOL1 are significantly expressed in the
pituitary gland. There has been some evidence and concerns that
COVID-19 may also damage the hypothalamo-pituitary-adrenal
axis that has been expressed by Pal,69 which may be connected with
the participation of the previously mentioned proteins.
Another surprising finding of the current work is the elevated
number of subdiffusive shortest paths that coincide with the short-
est (topological) paths connecting pairs of proteins in the PPI of
human proteins targeted by SARS-CoV-2. This means that the effi-
ciency of the diffusive paths connecting pairs of nodes in this PPI is
almost 98% in relation to a hypothetical process that uses the short-
est (topological) paths in propagating perturbations between pairs
of proteins. The 437 shortest diffusive paths reported here contain
one more edge than the corresponding shortest (topological) paths.
The proteins appearing in these paths would never be visited in the
paths connecting two other proteins if only the shortest (topologi-
cal) paths were used. What is interesting to note that 6 out of the 15
proteins that are mainly expressed outside the lungs are among the
ones “crossed” by these paths. They are TLE5 (thymus, lymph node,
testis), PKP2 (heart muscle), CEP135 (skeletal muscle, heart mus-
cle, cerebral cortex, cerebellum), CEP43 (testis), RBM41 (pancreas,
T-cells, testis, retina), and RETREG3 (prostate, thymus). This means
that the perturbation of these proteins occurs not only through the
diffusion from other proteins in the lungs directly to them, but also
through some “accidental” diffusive paths between pairs of proteins
that are both located in the lungs.
All in all, the use of time-fractional diffusive models to study
the propagation of perturbations on PPI networks seems a very
promising approach. The model is not only biologically sounded
but it also allows us to discover interesting hidden patterns of the
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interactions between proteins and the propagation of perturbations
among them. In the case of the PIN of human proteins targeted by
SARS-CoV-2, our current finding may help to understand potential
molecular mechanisms for the multi-organs and systemic failures
occurring in many patients.
V. EXPERIMENTAL VALIDATION
After this work was completed, Qiu et al.75 uploaded the
manuscript entitled “Postmortem tissue proteomics reveals the
pathogenesis of multiorgan injuries of COVID-19.” The authors
profiled the host responses to COVID-19 by means of quantitative
proteomics in postmortem samples of tissues in lungs, kidney, liver,
intestine, brain, and heart. They reported differentially expressed
proteins (DEPs) for these organs as well as virus-host PPIs between
23 virus proteins and 110 interacting DEPs differentially regulated
in postmortem lung tissues. According to their results, most DEPs
(70.5%) appears in the lungs, followed by kidney (16.5%). Addi-
tionally, Qiu et al.75 identified biological processes that were up- or
down-regulated in the six postmortem tissue types. They found that
most up-regulated processes in the lungs correspond to processes
related to the response to inflammation and to immune response.
However, pathways related to cell morphology, such as the estab-
lishment of endothelial barriers, were down-regulated in the lungs,
which was interpreted as a confirmation that the lungs are the
main focus of virus-host fights. Other fundamental processes in the
six organs analyzed postmortem were significantly down-regulated,
which include processes related to organ movement, respiration,
and metabolism.
From the 59 proteins that we reported here as the ones with the
largest effect on perturbing those 38 proteins identified in human
diseases (see Table S3 in the supplementary material), 18 were found
to be down-regulated in the lungs by Qiu et al.75 If we make the cor-
responding adjustment, by considering that Qiu et al.75 considered
110 instead of 209 proteins in the PPI, the previous number repre-
sents 58.1% of proteins predicted here and experimentally found as
down-regulated in the lungs. From the rest of the proteins, which
were not found as having the largest effect on perturbing proteins
identified in human disease, only 29.1% were reported by Qiu et al.75
to be down-regulated in the postmortem analysis of patients’ lungs.
Among the proteins reported in Table S3 of the supplementary
material and by Qiu et al., we have ARF6, RTN4, RAB7A, 6NG5,
REEP5, VPS11, RHOA, RAB5C, among others. Finally, among the
proteins mainly expressed outside the lungs that are predicted in this
work to be significantly perturbed, we have five that were found by
Qiu et al.75 to be up-regulated in the different organs analyzed by
them. From the proteins included in Table I, Qiu et al.75 reported the
following ones up-regulated: PKP2 (heart), REEP6 (liver), HOOK1
(several organs), ATP5ME (heart), and SLC27A2 (liver and kid-
ney). They also reported CEP43 (reported as FGFR1OP) as down-
regulated in the brain. We should remark that we have considered
here many more organs than the six ones studied by Qiu et al.75
VI. FUTURE WORK
There are no doubts that in considering a diffusive propaga-
tion of perturbations among proteins in a PPI, we have made a
FIG. 6. PI metaplex. In the metaplex, every node of the PPI corresponds to a
protein and its crowded intracellular space. There is an internal dynamics in the
nodes and an external between the nodes.
few simplifications and assumptions. Every protein is embedded
in an intracellular crowded environment, which drives its diffusive
mechanism. Nowadays, it is well-established that this environment
is conducive to molecular subdiffusive processes. As remarked by
Guigas and Weiss,27 far from obstructing cellular processes, sub-
diffusion increases the probability of finding a nearby target by a
given protein, and therefore, it facilitates protein–protein interac-
tions. The current approach can be improved using two recently
developed theoretical frameworks: (i) metaplexes and (ii) d-path
Laplacian operators on graphs.
A PPI metaplex,70 a 4-tuple ϒ = (V, E,I ,ω), where (V, E) is
a graph, ω = {j}
k
j=1 is a set of locally compact metric spaces j
with Borel measures µj, and I : V → ω is illustrated in Fig. 6. Then,
we define a dynamical ϒ = (V, E,I ,ω = {k}) on the metaplex as
a tuple (H,T ). Here, H =
{
Hv : L2 (I(v),µI(v)) → L2(I(v),
µI(v))}v∈V is a family of operators such that the initial value prob-
lem ∂tuv = Hv(uv), uv|t=0 = u0, is well-posed, and T = {Tvw}(v,w)∈E
is a family of bounded operators Tvw : L2(I(v),µI(v)) → L2(I(w),
µI(w)). This means that inside a node of the metaplex, we con-
sider one protein and its crowded intracellular space. Inside the
nodes, we can have a dynamics like a time-fractional diffusion
equation, the fractional Fokker–Planck equation, or any other in a
continuous space. The inter-nodes dynamics is then dominated by a
graph-theoretic diffusive model like the one presented here.
The second possible improvement to the current model can be
made by introducing the possibility of long-range interactions in the
inter-nodes dynamics in the PPI metaplex. That is, instead of con-
sidering the time-fractional diffusion equation, which only accounts
for subdiffusive processes in the graph, we can use the following
generalization, which incorporates the d-path Laplacian operators,71







x (t) , (23)
where Ld is a generalization of the graph Laplacian operator to
account for long-range hops between nodes in a graph, d is the
shortest path distance between two nodes, and s > 0 is a parame-
ter. This equation has never been used before except that for the
case α = 1 where superdiffusive behavior was proved in 1- and
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2-dimensional cases.72,73 Other approaches have also been recently
used for similar purposes in the literature.74
We then hope that the combination of metaplexes and time-
and space-fractional diffusive models do capture more of the details
of protein–protein interactions in crowded cellular environments.
SUPPLEMENTARY MATERIAL
See the supplementary material for a list of proteins targeted
by SARS-CoV-2, which are found in the database DisGeNet as dis-
playing “definitive” or “strong” evidence of participating in human
diseases. The Disease ID is the code of the disease in DisGeNet. A list
of proteins with the largest effect on perturbing those 38 proteins are
identified in human diseases. ptot is the sum of the probabilities that
the given protein activates those identified as having “definitive” or
“strong” evidence of being involved in a human disease. There is an
RNA expression overview for proteins targeted by SARS-CoV-2 and
mainly expressed outside the lungs. We select the top RNA expres-
sions in the four databases reported in The Human Protein Atlas.
There is a list of proteins mainly expressed outside the lungs and
their major activators, which are proteins mainly expressed in the
lungs.
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